On May 19, 2020 – STELLA PHARMA CORPORATION (Head office: Chuoku, Osaka City; President: Tomoyuki Asano) is pleased to announce that Steboronine intravenous drip bag 9000 mg/300 mL (Generic name: Borofalan [ 10B]; "Steboronine "), a boron drug for boron neutron capture therapy ("BNCT"1), has been listed on the National Health Insurance Drug Price List, as published in the Official Gazette today (May 19,2020). We are also pleased to announce that the product will be available for sale on May 20.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Ministry of Health, Labour and Welfare ("MHLW") in Japan designated Steboronin as a product subject to the "SAKIGAKE Designation System." Stella Pharma received approval on March 25, 2020, to manufacture and sell Steboronin for the treatment of locally unresectable recurrent or unresectable advanced head and neck cancer.